Comparison of clomipramine, alprazolam and placebo in the treatment of obsessive-compulsive disorder

D. J. Stein, Eric Hollander, L. S. Mullen, C. M. DeCaria, M. R. Liebowitz

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Forty-four patients with obsessive-compulsive disorder (OCD) were entered into a double-blind randomly assigned treatment protocol with clomipramine (CMI) or placebo. In addition, alprazolam was administered to 14 OCD patients in a separate open-treatment study. The response rate of patients completing treatment was 50 per cent with CMI, 19 per cent with placebo, and 18 per cent with alprazolam. Self-ratings of obsessive-compulsive symptoms in intent to treat and complete samples demonstrated a significantly greater benefit with CMI than with alprazolam. Ratings of depression and clinician ratings of obsessionality in both intent-to-treat and complete samples did not, however, indicate differences between the treatment groups.

Original languageEnglish (US)
Pages (from-to)389-395
Number of pages7
JournalHuman Psychopharmacology
Volume7
Issue number6
StatePublished - 1992
Externally publishedYes

Fingerprint

Alprazolam
Clomipramine
Obsessive-Compulsive Disorder
Placebos
Clinical Protocols
Therapeutics
Depression

Keywords

  • Alprazolam
  • Clomipramine
  • Obsessive compulsive disorder
  • Pharmacotherapy

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Comparison of clomipramine, alprazolam and placebo in the treatment of obsessive-compulsive disorder. / Stein, D. J.; Hollander, Eric; Mullen, L. S.; DeCaria, C. M.; Liebowitz, M. R.

In: Human Psychopharmacology, Vol. 7, No. 6, 1992, p. 389-395.

Research output: Contribution to journalArticle

Stein, D. J. ; Hollander, Eric ; Mullen, L. S. ; DeCaria, C. M. ; Liebowitz, M. R. / Comparison of clomipramine, alprazolam and placebo in the treatment of obsessive-compulsive disorder. In: Human Psychopharmacology. 1992 ; Vol. 7, No. 6. pp. 389-395.
@article{bef890eed45348059c476623f35b7f59,
title = "Comparison of clomipramine, alprazolam and placebo in the treatment of obsessive-compulsive disorder",
abstract = "Forty-four patients with obsessive-compulsive disorder (OCD) were entered into a double-blind randomly assigned treatment protocol with clomipramine (CMI) or placebo. In addition, alprazolam was administered to 14 OCD patients in a separate open-treatment study. The response rate of patients completing treatment was 50 per cent with CMI, 19 per cent with placebo, and 18 per cent with alprazolam. Self-ratings of obsessive-compulsive symptoms in intent to treat and complete samples demonstrated a significantly greater benefit with CMI than with alprazolam. Ratings of depression and clinician ratings of obsessionality in both intent-to-treat and complete samples did not, however, indicate differences between the treatment groups.",
keywords = "Alprazolam, Clomipramine, Obsessive compulsive disorder, Pharmacotherapy",
author = "Stein, {D. J.} and Eric Hollander and Mullen, {L. S.} and DeCaria, {C. M.} and Liebowitz, {M. R.}",
year = "1992",
language = "English (US)",
volume = "7",
pages = "389--395",
journal = "Human Psychopharmacology",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Comparison of clomipramine, alprazolam and placebo in the treatment of obsessive-compulsive disorder

AU - Stein, D. J.

AU - Hollander, Eric

AU - Mullen, L. S.

AU - DeCaria, C. M.

AU - Liebowitz, M. R.

PY - 1992

Y1 - 1992

N2 - Forty-four patients with obsessive-compulsive disorder (OCD) were entered into a double-blind randomly assigned treatment protocol with clomipramine (CMI) or placebo. In addition, alprazolam was administered to 14 OCD patients in a separate open-treatment study. The response rate of patients completing treatment was 50 per cent with CMI, 19 per cent with placebo, and 18 per cent with alprazolam. Self-ratings of obsessive-compulsive symptoms in intent to treat and complete samples demonstrated a significantly greater benefit with CMI than with alprazolam. Ratings of depression and clinician ratings of obsessionality in both intent-to-treat and complete samples did not, however, indicate differences between the treatment groups.

AB - Forty-four patients with obsessive-compulsive disorder (OCD) were entered into a double-blind randomly assigned treatment protocol with clomipramine (CMI) or placebo. In addition, alprazolam was administered to 14 OCD patients in a separate open-treatment study. The response rate of patients completing treatment was 50 per cent with CMI, 19 per cent with placebo, and 18 per cent with alprazolam. Self-ratings of obsessive-compulsive symptoms in intent to treat and complete samples demonstrated a significantly greater benefit with CMI than with alprazolam. Ratings of depression and clinician ratings of obsessionality in both intent-to-treat and complete samples did not, however, indicate differences between the treatment groups.

KW - Alprazolam

KW - Clomipramine

KW - Obsessive compulsive disorder

KW - Pharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=0026999157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026999157&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0026999157

VL - 7

SP - 389

EP - 395

JO - Human Psychopharmacology

JF - Human Psychopharmacology

SN - 0885-6222

IS - 6

ER -